International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: I. Current concerns
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Although clinical experience influences psychotropic drug treatment world‐wide, it has been underutilized because it has not been systematically gathered and widely disseminated. An international survey was conducted to help remedy this situation. One of the major objectives was to develop a representative body of expert judgment and opinion on the clinical use of benzodiazepines in relation to other psychotherapeutic medications that might be used for the same purposes. A select international panel of psychiatric experts on the pharmacotherapy of the anxiety and depressive disorders (N = 73) was constituted on the basis of progressive peer nominations. The peer selection process began with primary nominators from 44 countries. Judgments and opinions about psychotherapeutic medications were elicited from the Expert Panel via a self‐administered questionnaire. Completion rate: 90 per cent (66/73). Outcomes bear directly on current therapeutic and regulatory concerns. Topics addressed include: special indications for use, abuse liability, dependence potential, duration of treatment, high‐risk treatments, and adverse effects. Although sometimes divided, agreement was generally high and indicative of a good benefit to risk ratio for the benzodiazepines. Expert judgments were more positive than would have been anticipated from media reports, public concern, and recent regulatory postures. The following inferences can be drawn from this body of expert judgment and opinion: (1) qualitative differences in abuse liability among the benzodiazepines are minimal; (2) physical dependence at therapeutic doses is not a major clinical problem; (3) when physical dependence occurs, it can be readily managed clinically by the treating physician; (4) the relative abuse liability of the benzodiazepines as a class is low. These expert evaluations do not support or justify the imposition of stronger or differential restrictions on the benzodiazepines. The data help define the reasonable limits within which clinical guidelines and regulatory mandates can be meaningfully promulgated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Benzodiazepines: use, abuse, and consequences.
Woods, J. H., Katz, J. L., & Winger, G. (1992) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00468-5 · Cited by 560
Cited by
Linking Goal Progress and Subjective Well-Being: A Meta-analysis
Klug, H. J. P., & Maier, G. W. (2015) · Journal of Happiness Studies · doi:10.1007/s10902-013-9493-0 · Cited by 257
The reappraisal of benzodiazepines in the treatment of anxiety and related disorders
Starcevic, V. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.963057 · Cited by 90
Uhlenhuth, E. H., Balter, M. B., Ban, T. A., & Yang, K. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199912002-00005 · Cited by 80
Self-citationAn 87-year-old woman taking a benzodiazepine
Salzman, C. (1999) · JAMA · doi:10.1001/jama.281.12.1121 · Cited by 18
Metadata
- Authors
- Balter, M. B., Ban, T. A., & Uhlenhuth, E. H.
- Venue
- Human Psychopharmacology: Clinical and Experimental
- Publisher
- Wiley
- Published
- 1993-07
- Volume
- 8
- Issue
- 4
- Pages
- 253-261
- ISSN
- 0885-6222 (ISSN-L)
- 1099-1077
- OpenAlex
- W2055225450
- Cited by
- 22
- References
- 1
- FWCI
- 1.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: I. Current concerns. https://app.cochat.ai/papers/10.1002/hup.470080404
- The paper
- Balter, M. B., Ban, T. A., & Uhlenhuth, E. H. (1993). International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: I. Current concerns. Human Psychopharmacology: Clinical and Experimental. https://doi.org/10.1002/hup.470080404
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.